Sandhya Bejjanki, MD
Hematology & Oncology · Cleburne, TXNPI 1205037488
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 130 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 10.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,151, more than ten times the $14 reported in 2019. That places this record below the midpoint for hematology & oncology clinicians in TX, where the typical reported total is $3,204.
Across 130 payments — averaging $21.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$283
- Bristol Myers Squibb$227
- Novartis$220
- E.r. Squibb & Sons, L.L.C.$201
- Merck$135
- Bayer$113
- plus $2K from 34 others
What the payments were for
- Food & beverage$2,68098%
- Education$612%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 14 | $283 |
| Bristol Myers Squibb | 9 | $227 |
| Novartis | 10 | $220 |
| E.r. Squibb & Sons, L.L.C. | 10 | $201 |
| Merck | 5 | $135 |
| Bayer | 5 | $113 |
| Gilead | 5 | $99 |
| Daiichi Sankyo Inc. | 4 | $88 |
| Pfizer | 4 | $88 |
| Lilly USA, LLC | 5 | $88 |
| Pharmacosmos Therapeutics Inc. | 4 | $88 |
| Karyopharm Therapeutics Inc. | 4 | $75 |
| Genentech USA, Inc. | 3 | $72 |
| Eisai Inc. | 4 | $71 |
| Pharmaessentia USA Corporation | 2 | $68 |
| GSK | 4 | $68 |
| Array Biopharma Inc | 3 | $66 |
| Foundation Medicine, Inc. | 3 | $59 |
| Incyte Corporation | 3 | $58 |
| Regeneron Healthcare Solutions, Inc. | 2 | $55 |
| Seagen Inc. | 3 | $54 |
| Sobi, Inc | 2 | $48 |
| Stemline Therapeutics Inc. | 2 | $40 |
| Astellas Pharma US Inc | 2 | $38 |
| Acrotech Biopharma Inc. | 3 | $36 |
| Beone Medicines USA, Inc. | 1 | $31 |
| Recordati_rare_diseases_inc. | 1 | $31 |
| Caris MPI, Inc. | 1 | $27 |
| Geron Corporation | 1 | $25 |
| AVEO Pharmaceuticals, Inc. | 1 | $25 |
| Tempus AI, Inc | 1 | $24 |
| Servier Pharmaceuticals LLC | 1 | $21 |
| AbbVie | 1 | $20 |
| Amgen | 1 | $18 |
| Springworks Therapeutics, Inc. | 1 | $17 |
| Shield Therapeutics Inc | 1 | $16 |
| Boston Scientific | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| Sanofi | 1 | $14 |
| Sirtex Medical Inc | 1 | $6 |
How this compares
$2,742 in reported general payments places this provider in the 45th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 50 | $500,879 |
| JakafiRuxolitinib Phosphate | 23 | $461,233 |
| ImbruvicaIbrutinib | 13 | $212,604 |
| XtandiEnzalutamide | 15 | $189,485 |
| XareltoRivaroxaban | 29 | $21,240 |
| EliquisApixaban | 17 | $15,201 |
| Exemestane | 16 | $4,269 |
| Anastrozole | 243 | $2,976 |
| Ondansetron OdtOndansetron | 63 | $708 |
| Hydroxyurea | 37 | $659 |
| Potassium Chloride | 54 | $609 |
| Pantoprazole Sodium | 61 | $547 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 16 | $441 |
| Acyclovir | 59 | $428 |
| Morphine Sulfate ErMorphine Sulfate | 14 | $427 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $283 | $500,87950 claims |
| Incyte CorporationJakafi | $58 | $461,23323 claims |
| Astellas Pharma US IncXtandi | $38 | $189,48515 claims |
| Johnson & JohnsonXarelto | $14 | $21,24029 claims |
| PfizerEliquis | $88 | $15,20117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 838 hematology & oncology providers in Texas.
Other hematology & oncology in Cleburne
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
- Asad DeanFort Worth$1.1M
- Habte YimerTyler$934K
- Edward PearsonDallas$900K
- Naval DaverHouston$853K
- Christopher MaiselDallas$713K
- Clifton LaymanEl Paso$645K
- Jorge Cortes-FrancoHouston$627K
- Timothy FenskeSan Antonio$626K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.